Compare Dr. Reddys with Wockhardt - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs WOCKHARDT - Comparison Results

DR. REDDYS LAB     Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the pharmaceutical value chain - basic research, finished dosages, generics, bulk actives, and biotechnology. The company's business is mainly organized into Global g... More

WOCKHARDT 
   Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB WOCKHARDT DR. REDDYS LAB/
WOCKHARDT
 
P/E (TTM) x 35.1 -88.7 - View Chart
P/BV x 4.8 2.0 244.8% View Chart
Dividend Yield % 0.6 0.0 28,121.5%  

Financials

 DR. REDDYS LAB   WOCKHARDT
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-20
WOCKHARDT
Mar-18
DR. REDDYS LAB/
WOCKHARDT
5-Yr Chart
Click to enlarge
High Rs3,3631,012 332.3%   
Low Rs2,352532 442.5%   
Sales per share (Unadj.) Rs1,054.2355.9 296.2%  
Earnings per share (Unadj.) Rs121.9-60.3 -202.3%  
Cash flow per share (Unadj.) Rs190.2-46.8 -406.8%  
Dividends per share (Unadj.) Rs25.000.01 250,000.0%  
Dividend yield (eoy) %0.90 67,519.7%  
Book value per share (Unadj.) Rs938.7257.8 364.1%  
Shares outstanding (eoy) m166.17110.63 150.2%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.72.2 125.0%   
Avg P/E ratio x23.4-12.8 -183.1%  
P/CF ratio (eoy) x15.0-16.5 -91.0%  
Price / Book Value ratio x3.03.0 101.7%  
Dividend payout %20.50 -123,597.1%   
Avg Mkt Cap Rs m474,83185,379 556.1%   
No. of employees `00021.76.3 346.2%   
Total wages/salary Rs m33,8029,371 360.7%   
Avg. sales/employee Rs Th8,091.06,295.0 128.5%   
Avg. wages/employee Rs Th1,561.31,498.3 104.2%   
Avg. net profit/employee Rs Th935.8-1,066.3 -87.8%   
INCOME DATA
Net Sales Rs m175,17039,369 444.9%  
Other income Rs m6,2061,202 516.2%   
Total revenues Rs m181,37640,571 447.1%   
Gross profit Rs m24,42118 133,448.1%  
Depreciation Rs m11,3481,495 758.9%   
Interest Rs m9832,555 38.5%   
Profit before tax Rs m18,296-2,830 -646.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m5610-   
Extraordinary Inc (Exp) Rs m0-3,582 0.0%   
Tax Rs m-1,403257 -545.9%   
Profit after tax Rs m20,260-6,669 -303.8%  
Gross profit margin %13.90 29,992.1%  
Effective tax rate %-7.7-9.1 84.4%   
Net profit margin %11.6-16.9 -68.3%  
BALANCE SHEET DATA
Current assets Rs m125,99133,796 372.8%   
Current liabilities Rs m72,14126,917 268.0%   
Net working cap to sales %30.717.5 175.9%  
Current ratio x1.71.3 139.1%  
Inventory Days Days7379 92.1%  
Debtors Days Days10589 117.4%  
Net fixed assets Rs m83,85439,664 211.4%   
Share capital Rs m831553 150.2%   
"Free" reserves Rs m155,15727,968 554.8%   
Net worth Rs m155,98828,522 546.9%   
Long term debt Rs m1,30421,731 6.0%   
Total assets Rs m232,25381,620 284.6%  
Interest coverage x19.6-0.1 -18,240.9%   
Debt to equity ratio x00.8 1.1%  
Sales to assets ratio x0.80.5 156.4%   
Return on assets %9.1-5.0 -181.5%  
Return on equity %13.0-23.4 -55.6%  
Return on capital %12.6-7.7 -164.4%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m84,1939,807 858.5%   
Fx outflow Rs m39,6161,789 2,214.9%   
Net fx Rs m44,5778,019 555.9%   
CASH FLOW
From Operations Rs m29,841684 4,360.2%  
From Investments Rs m-4,9236,302 -78.1%  
From Financial Activity Rs m-25,159-7,695 327.0%  
Net Cashflow Rs m-266-664 40.1%  

Share Holding

Indian Promoters % 25.5 74.5 34.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.4 2.3 234.8%  
FIIs % 35.3 7.7 458.4%  
ADR/GDR % 18.5 0.1 18,500.0%  
Free float % 15.3 15.4 99.4%  
Shareholders   75,885 67,757 112.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   WYETH  IPCA LABS  JUBILANT PHARMOVA   SUN PHARMA  PIRAMAL ENTERPRISES  

Compare DR. REDDYS LAB With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Tumbles 600 Points Tracking Global Selloff; HDFC & Tata Steel Top Losers(09:30 am)

A fresh spike in US bond yields and a firm dollar triggered a selloff in Asian share markets today.

Related Views on News

WOCKHARDT Announces Quarterly Results (3QFY20); Net Profit Up 125.0% (Quarterly Result Update)

Jan 28, 2020 | Updated on Jan 28, 2020

For the quarter ended December 2019, WOCKHARDT has posted a net profit of Rs 192 m (up 125.0% YoY). Sales on the other hand came in at Rs 9 bn (down 16.9% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

WOCKHARDT Announces Quarterly Results (1QFY20); Net Profit Up 57.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, WOCKHARDT has posted a net profit of Rs 369 m (up 57.2% YoY). Sales on the other hand came in at Rs 9 bn (down 14.3% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

WOCKHARDT Announces Quarterly Results (4QFY19); Net Profit Up 90.8% (Quarterly Result Update)

May 7, 2019 | Updated on May 7, 2019

For the quarter ended March 2019, WOCKHARDT has posted a net profit of Rs 139 m (up 90.8% YoY). Sales on the other hand came in at Rs 10 bn (down 3.8% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

WOCKHARDT Announces Quarterly Results (3QFY20); Net Profit Up 125.0% (Quarterly Result Update)

Jan 28, 2020 | Updated on Jan 28, 2020

For the quarter ended December 2019, WOCKHARDT has posted a net profit of Rs 192 m (up 125.0% YoY). Sales on the other hand came in at Rs 9 bn (down 16.9% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

WOCKHARDT Announces Quarterly Results (1QFY20); Net Profit Up 57.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, WOCKHARDT has posted a net profit of Rs 369 m (up 57.2% YoY). Sales on the other hand came in at Rs 9 bn (down 14.3% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Make Rs 5,000 Per Day Trading the Market(Fast Profits Daily)

Feb 25, 2021

In this video, I'll show you how to get started on the path to daily trading profits.

I Believe the Investment of the Year Will Be...

Feb 19, 2021

In this episode, ace trader Brijesh Bhatia talks to us about the best investments of 2021, his profitable trading system, and much more.

The Hidden Tesla in My Great Indian Wealth Project(Profit Hunter)

Feb 23, 2021

An Indian company founded three decades ago in a garage caught my attention...

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Mar 4, 2021 11:18 AM

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB - JUBILANT PHARMOVA COMPARISON

COMPARE DR. REDDYS LAB WITH

MARKET STATS